Abbreviated Name

BBD Ref Set App: Marks (2015)

Lead Investigator

Marks, Jeffrey — Duke University Medical Center

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Godwin, Andrew K — University of Kansas Medical Center
• Marks, Jeffrey — Duke University Medical Center

Abstact

Aims

We propose that two of the highest value markers based on published data (KI-67 and EZH2) will be performed by both Duke and Kansas.

Analytic Method

Our main BBD protocol argues that in order to be useful a biomarker should have a TPR/FPR ratio of at least 2.0, where TPR is the marker’s sensitivity and FPR is 1-specificity.

Biomarkers

• ALDH1A1
• CDKN2A (p16)
• CEACAM6
• EZH2
• GSTM1
• HYAL1
• MKI67
• MMP1
• PGR
• PTGS2
• TP53

Data Collections

• No data available at this time for this protocol

 Team Project

Protocol ID

402

Protocol Type

Reference Set

Field of Research

Proteomics

Collaborative Group

Breast and Gynecologic Cancers Research Group

Cancer Types

• Malignant neoplasm of breast